In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
